Immunotherapeutic Strategies in Tumor Microenvironments

The tumour microenvironment is a dynamic ecosystem in which malignant cells, stromal elements and infiltrating immune cells interact through a network of cytokines, chemokines and cell–cell contacts. Contemporary immunotherapeutic strategies seek to re-educate or invigorate endogenous immunity against cancer by targeting key regulatory axes within this milieu. Approaches include blockade of inhibitory receptors on T cells, modulation of antigen presentation, engineering of adaptive cell therapies and rational design of vaccine platforms to enhance neoantigen recognition. Further refinements exploit bispecific antibodies to localise immune activation to the tumour core, chemokine fusion constructs to recruit effector populations and Fc-region engineering to tune antibody–receptor engagement. Combination regimens that integrate checkpoint inhibitors with vaccines or cell therapies have shown marked synergistic effects, underscoring the importance of a multipronged assault on immune evasion mechanisms. Ultimately, success hinges on the precise remodelling of suppressive niches, amplification of cytotoxic programmes and preservation of immune memory.

Research from Nature Portfolio

A systematic meta-analysis of regulatory T-cell infiltration across multiple solid tumours has resolved their context-dependent prognostic value. High densities of FoxP3+ Tregs generally predict poorer survival in cancers such as melanoma and renal carcinoma, whereas in colorectal and head and neck tumours they correlate with improved outcomes. Stratification according to molecular subtype and tumour stage further refines prognostic estimates and suggests that selective depletion of intratumoural Tregs may strengthen responses to immunotherapy. This global analysis provides a framework for patient stratification, guiding the development of therapies that modulate Treg abundance in a tumour-specific manner.

Immunotherapeutic Strategies in Tumor Microenvironments publication trend

The graph below shows the total number of articles in immunotherapeutic strategies in tumor microenvironments across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour microenvironment (TME): The complex milieu of cancerous cells, stromal components, immune infiltrates and soluble mediators that collectively influence tumour growth and therapy response.

Immune checkpoint inhibitors: Monoclonal antibodies that block inhibitory receptors such as CTLA-4 or PD-1 on T cells, thereby restoring anti-tumour immunity.

Regulatory T cells (Tregs): A specialised CD4+ T-cell subset that suppresses immune activation and can impede effective anti-tumour responses.

Bispecific antibody: A recombinant construct engineered to bind two distinct antigens, enabling precise localisation of immune effector activities in the tumour.

Fc gamma receptors (FcγRs): Cell surface receptors on innate immune cells that recognise the Fc domain of antibodies and regulate processes such as antibody-dependent cellular cytotoxicity.

References

1. Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response. Molecular Cancer (2024).
2. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Scientific Reports (2015).
3. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer (2020).
4. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. Journal for ImmunoTherapy of Cancer (2019).